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Abstract
Background: Surgery of malignant tumors has long been suspected to be the reason for enhancement of
growth of metastases with fatal outcome. This often prevented surgeons from touching the tumor if not
absolutely necessary. We have shown in lung cancer patients that surgery, itself, leads to mobilization of
tumor cells into peripheral blood. Some of the mobilized cells finding an appropriate niche might grow to
form early metastases. Monitoring of tumor cell release during and the fate of such cells after surgery for
breast cancer may help to reveal how metastases develop after surgery.
Method: We used the MAINTRAC® analysis, a new tool for online observation of circulating epithelial
cells, to monitor the number of epithelial cells before, 30 min, 60 min, three and seven days after surgery
and during subsequent variable follow up in breast cancer patients.
Results: Circulating epithelial cells were already present before surgery in all patients. During the first 30–
60 min after surgery values did not change immediately. They started increasing during the following 3 to
4 days up to thousand fold in 85% of treated patients in spite of complete resection of the tumor with
tumor free margins in all patients. There was a subsequent re-decrease, with cell numbers remaining above
pre-surgery values in 58% of cases until onset of chemotherapy. In a few cases, where no further therapy
or only hormone treatment was given due to low risk stage, cell numbers were monitored for up to three
years. They remained elevated with no or a slow decrease over time. This was in contrast to the
observation in a patient where surgery was performed for benign condition. She was monitored before
surgery with no cells detectable. Epithelial cells increased up to more than 50 000 after surgery but
followed by a complete reduction to below the threshold of detection.
Conclusion: Frequently before but regularly during surgery of breast cancer, epithelial cells are mobilized
into circulation. Part of these cells, most probably normal or apoptotic cells, are cleared from the
circulation as also shown to occur in benign conditions. After resection even if complete and of small
tumors, cells can remain in the circulation over long times. Such cells may remain "dormant" but might
settle and grow into metastases, if they find appropriate conditions, even after years.
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Surgery of malignant breast tumors aims at eliminating
most of the malignant cells. Adjuvant therapy is applied
subsequently in most cases due to the assumption that
not all malignant cells have been removed. This approach
has proven successful also after 30 years of survey [1]. The
question arises when these cells have been mobilized into
circulation. Klein et al [2] claim that the low genetic vari-
ation of the circulating cells as compared to the tumor
itself indicates that cells have left the tumor at an early
stage. We can, indeed, detect circulating tumor cells
already before surgery treatment in all patients so far
assessed [3]. "Dormant" tumor cells can be present in the
circulation for years without leading to relapse [4,5]. In a
report from the data from 30 years of survey [6] it is
assumed that early relapses in a subpopulation of breast
cancer patients are due to preexisting dormant metastases
which can be activated and are induced to growth and/or
vascularization by the act of surgery. Recent calculations
of the hazard of recurrence in a retrospective study are
indicative of acceleration of the metastatic process in
some patients by the surgical resection of the primary
breast cancer. It is assumed that this phenomenon may be
due to release of preexistent tumor cells or of micrometa-
static single cells and avascular foci present in the patients
before diagnosis from dormancy. The detection of such
"dormant" cells in bone marrow seems to have impact on
prognosis and relapse free survival [7]. They can be
detected in 25% of patients, 40% of which will relapse
whereas the other 60% although they also have such cells
in their bone marrow will be spared from relapse. Thus,
demonstration of bone marrow epithelial cells is not suf-
ficient for the individual patient to predict relapse [8]. It is
possible that the route and time of seeding contribute to
the final outcome. Therefore we have analyzed how sur-
gery effects the level of circulating epithelial cells in differ-
ent patients using our approach for real-time monitoring
of changes in the number of circulating tumor cells [9,10].
These analyses may contribute to our understanding of
how surgery influences the course of disease in breast can-
cer.
Patients and methods
Fifty two consecutive patients with newly diagnosed
breast cancer of all stages were included. Stages were as
follows: 2 patients with DCIS, 24 patients with T1N0 and
2 patients with T1N1; 6 patients with T2N0 and 5 patients
with T2N1; 2 patients with T3, 7 patients with T4, 2
relapsed patients, 2 patients after cryotherapy.
Once informed consent had been obtained from all par-
ticipants, as required for ethics committee approval,
peripheral blood anticoagulated with EDTA was drawn
before each intervention such as surgery, at day 3(4) and
day 7 after surgery and at intervals of several months
thereafter. First, red blood cells were lysed using ammo-
nium chloride, which was followed by a single centrifuga-
tion step. Then, the pellet of white cells was collected (in
accordance with a previously described approach [10] and
incubated with FITC-conjugated mouse anti-human epi-
thelial antibody (HEA; Miltenyi Bergisch Gladbach, Ger-
many) for 15 min in the dark and readjusted to 1 ml. 20
µl of this suspension of unfixed vital cells were used for
measurements applied to a poly-L-lysine treated slide,
which was analyzed using a Laser Scanning Cytometer®
(Compucyte Corporation, Cambridge, MA, USA) [10].
Measurements of a defined area were started when the
cells had settled and took about 5 min according to cell
density. For optimal measurements it was imperative to
have a single cell suspension with about 2–3 cell diame-
ters space between the cells. The adherent cells were meas-
ured using a Laser Scanning Cytometer (LSC® Compucyte
Corporation, Cambridge, MA, USA). The cells could easily
and unequivocally be contoured using forward scatter as
a thresholding parameter at 20× magnification. Back-
ground fluorescence was determined dynamically to cal-
culate both peak and integral fluorescence on a per-cell
basis. This unique method corrects for variation in back-
ground fluorescence and makes the fluorescent calcula-
tion equivalent for all cells. The FITC-HEA positive cell
fluorescence was collected using a 530/30 nm bandpass
filter and amplified using a photomultiplier (PMT). Val-
ues are displayed as scattergrams and histograms and per-
centages and mean values of positive and negative cells
calculated from the region comprised of single cells only.
The LSC® enables the user to relocate cells contained
within the positive population for visual examination
through the microscope. In addition a CCD camera
attached to the microscope allowed taking photo- and
fluoromicrographs at the same time [9]. This method,
termed MAINTRAC® analysis, enables relocation of cells
for visual examination discrimination of live and dying
cells and quantification, and for taking fluoromicro-
graphs. Statistics were calculated according to the stu-
dent's T-test.
Results
Viability of the cells detected was always visually verified
looking for exclusive surface staining but also substanti-
ated by the long persistence in blood. Typical pictures of
such cells detected by their green fluorescing cap are
shown in Figure 1. Pre-therapy numbers varied considera-
bly between patients from 47160 to 200 cells/ml. No cor-
relation was found between tumor size or stage and
number of circulating cells (table 1). It should be men-
tioned that two patients with DCIS, too, had considerable
numbers of circulating epithelial cells already before sur-
gery.Page 2 of 7
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every time point were normalized and the effect of surgery
on circulating epithelial cell numbers was investigated. In
11 patients who were monitored before and 10 and 30
min after surgery the immediate release of cells during sur-
gery was analyzed. As seen from Figure 2 there was almost
no change in cell numbers during this early time after sur-
gery. Surprisingly, however, cell numbers increased
steeply in 85% of patients versus day 3 after surgery (Fig-
ure 3). Such an increase in circulating epithelial cells
might be due to mobilization of normal epithelial cells
during wound healing therefore cell numbers were again
monitored 7 days after surgery. Indeed, there was a re-
decrease in 58% of patients versus day 7 after surgery but
pre-surgery values were reached only in 38% of cases (Fig-
ure 3). All other patients had cell numbers remaining
above pre-surgery values. The two patients with DCIS and
the two patients receiving cryotherapy belonged to the
group of patients who did not increase in epithelial cell
numbers after surgery but their numbers remained
remarkably stable during this time (Figure 3 two fat lines).
15 patients could be further monitored until onset of
adjuvant therapy. Only in four of them cell numbers
decreased below pre-surgery values, in the others numbers
remained stable after day 7 or even further increased (Fig-
ure 4). This indicates that the release of cells into circula-
tion observed at day 3 is not only due to dying or normal
adjacent cells rapidly eliminated from peripheral blood
but obviously also long-lived cells are seeded into the cir-
culation. These patients included 3 patients with
advanced tumors (T2-4, N+) who already shortly after sur-
Increase and decrease of circulating cells of 25 patients before and 3 and 6 days after surgery for breast cancer set-ting pre-surgery valu s 100%Figure 3
Increase and decrease of circulating cells of 25 patients 
before and 3 and 6 days after surgery for breast cancer set-
ting pre-surgery values 100%. The fat dotted line with 
squares represents the mean increase and decrease of all 25 
patients. Two patients (one during cryotherapy and one with 
DCIS (fat lines) retain identical numbers during intervention.
Table 1: Mean values of pre-surgery epithelial cell numbers of 
patients.
T1(n = 27) T>1(n = 23) p
Mean value 6233 ± 5601 10818 ± 7102 0.1637
N0(69%) N1-3(31%) p
Mean value 6756 ± 5624 12008 ± 8465 0.1672
ER+(81%) ER-(19%) p
Mean value 9501 ± 7827 5955 ± 4935 0.4298
DCIS(n = 2)
Mean value 12100
Mean values of pre-surgery epithelial cell numbers of patients with 
different tumor sizes, involvement of lymph nodes and expression of 
estrogen receptor
Positively stained gated green fluorescing cells which have been r ocalized and visually analyz dFigure 1
Positively stained gated green fluorescing cells which have 
been relocalized and visually analyzed. Typical pictures of 
such cells detected by their green fluorescing cap are shown.
Analysis of the number of circulating cells from 11 patients immediately before and 30 and 60 min afte  surgeryFigure 2
Analysis of the number of circulating cells from 11 patients 
immediately before and 30 and 60 min after surgery.Page 3 of 7
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lial cells and have relapsed in spite of adjuvant
chemotherapy. Two patients with ER- tumors showed
decreasing cell numbers and after adjuvant chemotherapy
are still in complete remission.
Most patients received adjuvant therapy after surgery,
therefore natural survival of circulating cells without treat-
ment could be monitored only in 7 patients, in which no
further treatment was given apart from Tamoxifen due to
good prognostic markers. In these patients cell numbers
remained high, decreasing slowly in 4 patients including
one patient with DCIS but have been observed at the same
high level now during three years in two patients without
signs of relapse (Figure 5). This is in contrast to a patient
without epithelial malignancy who has been operated on
for biliary calculus. Before surgery no circulating epithelial
cells were detected in her blood, increasing to high num-
bers right after surgery remaining high for more than three
months, but then returned to below detectable numbers
even in repeated analyses (Figure 5).
Discussion
Circulating epithelial cells can be detected in many
patients with solid tumors but rarely in healthy subjects
[10]. Since most solid tumors are of epithelial origin or
have an epithelial component, it is assumed that these cir-
culating epithelial cells are shed from the tumor. There-
fore, we investigated how different diagnostic and
therapeutic interventions during the course of disease
influence the number of epithelial cells in the blood
stream. Circulating cells were present in almost all
patients already before surgery.
At the analyses 10 and 30 min after surgery cell numbers
remained at almost identical levels as before surgery indi-
cating that there was no significant early wash out of cells
into the circulation in the patients operated on in our
institution as an immediate consequence of surgery. In
contrast at day 3 to 4 after surgery, an increase in epithelial
cell numbers was observed in the vast majority of patients.
If normal surrounding cells were shed into circulation due
to wound healing these cells would be expected to be
% of pre-surgery values of recirulating cells until onset of adjuvant chemotherapyFigure 4
% of pre-surgery values of recirulating cells until onset of adjuvant chemotherapy.Page 4 of 7
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case for part of the cells until day 7. In some patients,
however, cell numbers further increased and even in
patients with re-decreasing cell numbers, pre-surgery val-
ues were rarely attained and levels of cell numbers
remained elevated even after prolonged times independ-
ent of tumor size. Part of the cells seemed to remain stably
in the circulation and this was true also for patients with
DCIS. They may be malignant cells capable to survive. It is
not known, to what extend they are able to form metas-
tases [11] but if growing aggressively they might contrib-
ute to metastasis formation as seen in three patients with
increasing cell numbers who suffered relapse. This may be
one reason for the screening paradox of young breast can-
cer patients [12].
It has been claimed that tumor cells have a short half life
[4]. If pre-surgery cell levels had been due to constant
replenishing of the blood with cells from the tumor these
cells would have been expected to rapidly decrease after
removal of the primary tumor. Obviously, however, long-
lived cells, presumably tumor cells, in addition to short-
lived epithelial cells, were shed into the circulation prob-
ably already before surgery and following surgery and
were detectable in the circulation even after extended
times until adjuvant therapy.
Short lived epithelial cells would rather be expected to be
normal cells shed into circulation during wound healing.
This was substantiated by our observation during moni-
toring of a patient without an epithelial tumor. This
patient had been monitored as a control with a systemic
hematological disorder and been repeatedly negative, but
suddenly showed a steep increase in circulating epithelial
cells when she underwent surgery for a biliary calculus.
Cell numbers returned to negativity only after about hun-
dred days which is compatible with a more delayed
wound healing after this treatment, but then remained
negative.
Thus, even benign cells seem to be mobilized into circula-
tion [13,14] and our results indicate that they are cleared
from blood and cell numbers return to below detection
after completion of wound healing. In breast cancer
patients, in contrast, cell numbers remained elevated or
even increased until adjuvant therapy. In the few patients
Numbers of longtime recirculating cells in patients without adjuvant chemotherapyFigur  5
Numbers of longtime recirculating cells in patients without adjuvant chemotherapy. Two patients (orange and blue (DCIS) line) 
have now been monitored more than three years always revealing almost identical number of recirculating cells. In contrast, in 
a patient without a solid tumor (dotted line) who underwent surgery for a benign condition, cells returned to below the 
threshold of detection without further treatment.Page 5 of 7
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therapy cell numbers remained at the same high level and
in two patients have remained at this level even after three
years of observation. Our results are in contradiction to
the hypothesis, that tumor cells detectable even after 20
years of complete remission are constantly replenished
from hidden micrometastases and rather favor the
assumption that these cells can re-circulate in a "dormant"
state for long times without leading to relapse, not only
due to the inability of settled cells to form blood vessels
[15] but also due to inefficiency of the preceding steps
[16-18]. A single analysis detection circulating epithelial
cells, in our opinion, therefore can not predict relapses.
The present results, showing that patients with further
increasing cell numbers after surgery, as previously also
demonstrated for non small cell lung cancers [19], tend to
relapse early, corroborate the requirement for repeated
analysis.
We were not able to distinguish benign and malignant
epithelial cells by surface antigen staining or morphology.
Reports, observing a rapid decline of epithelial cells after
surgery, therefore, might look at the elimination of benign
and dying malignant cells. Gene analysis at that time may
also include benign cells present around diagnosis and
surgery and this may make results of genetic variability
ambiguous [20].
The surgical management of breast cancer is rapidly evolv-
ing towards less invasive procedures [21]. Indeed, in two
patients, treated with cryotherapy, no additional cells
were released after this manipulation. The role of the
released cells for the patient's course of disease is not clear
but they might be the source of subsequent metastases
[22]. According to our criteria of exclusive surface staining
the cells were still viable. These cells are then the target of
adjuvant therapy but such treatment might be inefficient
as long as the cells are not in the cell cycle. Recent calcula-
tions indicate that these cells might grow in an irregular
fashion [23] making repeated analyses necessary for mon-
itoring their activity.
Tight tracing and quantification of circulating tumor cells
might, therefore, it becomes an essential tool for therapy
monitoring in solid tumors.
Moreover, peripheral blood being a transport medium
with its load is influenced by influx from e. g. tumor and
efflux into different organs, analysis of circulating tumor
cells during tumor development may open a whole new
field in experimental follow up of tumor progress and
possibly metastasis development.
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